TREET

• Research type

  Research Study

• Full title

  Randomized Controlled Multi-Center Non- Inferiority Trial of UI-EWD (Nexpowder TM) vs. Conventional Treatment as First-Line Endoscopic Therapy for Patients with High-Risk Nonvariceal Upper Gastrointestinal Bleeding (TREET)

• IRAS ID

  338716

• Contact name

  Geraldine Kelly

• Contact email

  geraldine.kelly@medtronic.com

• Sponsor organisation

  Medtronic

• Clinicaltrials.gov Identifier

  NCT06188585

• Duration of Study in the UK

  3 years, 1 months, 1 days

• Research summary

  The main purpose of this clinical study is to demonstrate that Nexpowder™, when used first, is similar to other approved endoscopic therapies for the treatment of patients with high-risk peptic ulcer bleeding.

  Nexpowder is a single-use device made up of a delivery system and a haemostatic powder, that works to stop the flow of blood.

  This study will randomly assign patients who present with peptic ulcer bleeding to receive treatment with either Nexpowder or with the standard treatment of thermal therapy, injection therapy, or mechanical therapy i.e. clips.
  

• REC name

  West of Scotland REC 4

• REC reference

  24/WS/0062

• Date of REC Opinion

  31 Jul 2024

• REC opinion

  Further Information Favourable Opinion